Exelixis’ 2026 EPS Estimate Rises to $3.39 as Shares Gain 31.1%
Analysts have raised Exelixis’ 2026 EPS estimate from $3.18 to $3.39 over the past 60 days, reflecting growing confidence in its oncology portfolio. Shares have climbed 31.1% over the past year, bolstered by four consecutive quarterly earnings beats averaging a 21.39% surprise.
1. EPS Estimate Upgrade
Over the past two months, analysts have lifted Exelixis’ 2026 earnings per share forecast from $3.18 to $3.39, reflecting optimism around its late-stage oncology candidates and expected revenue growth from key products.
2. Share Price Performance
Exelixis shares have surged 31.1% over the last year, outperforming the broader biotech sector amid consistent pipeline progress and investor confidence in upcoming trial readouts.
3. Consistent Earnings Beats
The company has beaten consensus estimates in each of the past four quarters, delivering an average surprise of 21.39%, driven by higher-than-expected product sales and operating efficiency improvements.